Barclays' analysts believe late entrants can still achieve n...

Barclays' analysts believe late entrants can still achieve notable sales in obesity drug market. Jefferies analysts find the acquisition aligns with Roche's strategy to fortify its pipeline and note the potential for combination with Roche's muscle-preserving candidates.